CA3179038A1 - Coronavirus vaccines - Google Patents
Coronavirus vaccinesInfo
- Publication number
- CA3179038A1 CA3179038A1 CA3179038A CA3179038A CA3179038A1 CA 3179038 A1 CA3179038 A1 CA 3179038A1 CA 3179038 A CA3179038 A CA 3179038A CA 3179038 A CA3179038 A CA 3179038A CA 3179038 A1 CA3179038 A1 CA 3179038A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- residues
- residue
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004826.0A GB202004826D0 (en) | 2020-04-01 | 2020-04-01 | Coronavirus vaccines |
| GB2004826.0 | 2020-04-01 | ||
| GB2010672.0 | 2020-07-10 | ||
| GBGB2010672.0A GB202010672D0 (en) | 2020-07-10 | 2020-07-10 | Coronovirus vaccines |
| GBGB2015775.6A GB202015775D0 (en) | 2020-10-05 | 2020-10-05 | Coronavirus vaccines |
| GB2015775.6 | 2020-10-05 | ||
| GB2101824.7 | 2021-02-10 | ||
| GBGB2101824.7A GB202101824D0 (en) | 2021-02-10 | 2021-02-10 | Coronavirus vaccines |
| GB2103214.9 | 2021-03-08 | ||
| GBGB2103214.9A GB202103214D0 (en) | 2021-03-08 | 2021-03-08 | Coronavirus vaccines |
| PCT/GB2021/050830 WO2021198706A2 (en) | 2020-04-01 | 2021-04-01 | Coronavirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179038A1 true CA3179038A1 (en) | 2021-10-07 |
Family
ID=75426636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179038A Pending CA3179038A1 (en) | 2020-04-01 | 2021-04-01 | Coronavirus vaccines |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12691172B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126033A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023522156A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116113431A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021249525A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179038A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021198706A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| CN113527444B (zh) * | 2020-04-13 | 2022-12-27 | 中国科学院微生物研究所 | 与新型冠状病毒的抗体有效结合的表位 |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| WO2022266012A1 (en) * | 2021-06-14 | 2022-12-22 | Modernatx, Inc. | Coronavirus glycosylation variant vaccines |
| AU2022358982A1 (en) * | 2021-10-06 | 2024-05-23 | Diosynvax Ltd | Coronavirus vaccines |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024184626A2 (en) | 2023-03-03 | 2024-09-12 | Diosynvax Ltd | Coronavirus vaccines |
| WO2024209218A1 (en) * | 2023-04-05 | 2024-10-10 | Diosynvax Ltd | Coronavirus vaccines inducing broad immunity against variants |
| WO2025083402A1 (en) * | 2023-10-16 | 2025-04-24 | Diosynvax Ltd | Coronavirus vaccines |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| US20080027006A1 (en) | 2004-02-12 | 2008-01-31 | The Regents Of The University Of Colorado | Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity |
| CN1884303A (zh) * | 2005-06-20 | 2006-12-27 | 中国医学科学院基础医学研究所 | SARS-CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途 |
| CN102690336A (zh) * | 2012-06-11 | 2012-09-26 | 中国科学院武汉病毒研究所 | 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途 |
| WO2015143335A1 (en) * | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| CN106928326B (zh) | 2015-12-31 | 2019-12-24 | 中国科学院微生物研究所 | 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗 |
| CN112088014B (zh) * | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
| JP6732856B2 (ja) | 2018-10-31 | 2020-07-29 | みずほ情報総研株式会社 | プーリング管理システム、プーリング管理方法及びプーリング管理プログラム |
| DE202021004130U1 (de) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| MX2023007574A (es) * | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| WO2023275538A1 (en) | 2021-06-28 | 2023-01-05 | Diosynvax Ltd | Beta-coronavirus vaccines |
-
2021
- 2021-04-01 WO PCT/GB2021/050830 patent/WO2021198706A2/en not_active Ceased
- 2021-04-01 JP JP2022560285A patent/JP2023522156A/ja active Pending
- 2021-04-01 AU AU2021249525A patent/AU2021249525A1/en active Pending
- 2021-04-01 US US17/916,369 patent/US12691172B2/en active Active
- 2021-04-01 CN CN202180039232.6A patent/CN116113431A/zh active Pending
- 2021-04-01 CA CA3179038A patent/CA3179038A1/en active Pending
- 2021-04-01 EP EP21717190.9A patent/EP4126033A2/en active Pending
-
2025
- 2025-09-29 JP JP2025162640A patent/JP2025184979A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126033A2 (en) | 2023-02-08 |
| JP2025184979A (ja) | 2025-12-18 |
| CN116113431A (zh) | 2023-05-12 |
| US20240285751A1 (en) | 2024-08-29 |
| AU2021249525A1 (en) | 2022-12-08 |
| WO2021198706A2 (en) | 2021-10-07 |
| US12691172B2 (en) | 2026-07-28 |
| WO2021198706A3 (en) | 2021-12-02 |
| JP2023522156A (ja) | 2023-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021198706A2 (en) | Coronavirus vaccines | |
| Shang et al. | Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies | |
| US20240226012A1 (en) | Novel multivalent nanoparticle-based vaccines | |
| Seephetdee et al. | A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera | |
| CN111671890B (zh) | 一种新型冠状病毒疫苗及其应用 | |
| Xu et al. | Antibodies and vaccines against Middle East respiratory syndrome coronavirus | |
| Guy et al. | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward | |
| Schmitz et al. | Next generation dengue vaccines: a review of candidates in preclinical development | |
| CA3170575A1 (en) | Vaccines against sars-cov-2 and other coronaviruses | |
| Law et al. | SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1 | |
| CN116472279A (zh) | 麻疹载体covid-19免疫原性组合物和疫苗 | |
| JP2021536228A (ja) | ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター | |
| Zhou et al. | Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines | |
| US20240269261A1 (en) | Expression of sars-cov proteins, nucleic acid constructs, virus like proteins (vlps) and methods relevant thereto | |
| Salleh | Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development | |
| Wang et al. | Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice | |
| Koch et al. | The COVID-19 vaccine landscape | |
| Vishwakarma et al. | Severe acute respiratory syndrome coronavirus 2 spike protein based novel epitopes induce potent immune responses in vivo and inhibit viral replication in vitro | |
| US20250312437A1 (en) | Coronavirus vaccines | |
| Escalante | Multivalent Prophylactic Vaccines Against Epstein-Barr Virus Infection and Its Associated Diseases | |
| Zhang et al. | Severe acute respiratory syndrome: vaccine on the way | |
| Pantano | Development of BSL-2 platforms for the identification of pan-neutralizing human monoclonal antibodies against Coronaviridae | |
| Lee et al. | Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challenges | |
| Wrapp | Structural Insights into Coronavirus Spike Proteins and Implications for Therapeutic Interventions | |
| Wang et al. | Crimean-Congo hemorrhagic fever virus protein GP38 from isolate M18-China confers broad immunological breadth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250401 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250404 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250521 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250521 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250523 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20260310 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20260310 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20260310 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260310 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260327 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260327 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260414 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260729 |